|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-10-1
|
|
pubmed:abstractText |
Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of alpha-Gal A antibodies in treated patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1589-95
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15458455-Cross Reactions,
pubmed-meshheading:15458455-Fabry Disease,
pubmed-meshheading:15458455-Female,
pubmed-meshheading:15458455-Humans,
pubmed-meshheading:15458455-Immunoglobulin G,
pubmed-meshheading:15458455-Isoenzymes,
pubmed-meshheading:15458455-Male,
pubmed-meshheading:15458455-Neutralization Tests,
pubmed-meshheading:15458455-Recombinant Proteins,
pubmed-meshheading:15458455-Trihexosylceramides,
pubmed-meshheading:15458455-alpha-Galactosidase
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
|
|
pubmed:affiliation |
Department of Internal Medicine/Clinical Hematology, Academic Medical Center, Amsterdam, The Netherlands. G.E.Linthorst@amc.uva.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
